Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 15/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27912952 | 0.87 | FPR2 (0.40) | FPR2HRH3HDAC6 | |
| SCHEMBL2328554 | 0.85 | FPR2 (0.50) | FPR2HRH3HDAC6 | |
| SCHEMBL1703915 | 0.80 | FPR2 (0.50) | FPR2HRH3HDAC6 | |
| SCHEMBL27851166 | 0.78 | FPR2 (0.36) | FPR2HRH3 | |
| SCHEMBL1704174 | 0.76 | MAPT (0.40) | FPR2HRH3 | |
| SCHEMBL1167220 | 0.76 | FPR2 (0.51) | FPR2HRH3HDAC6 | |
| SCHEMBL9901605 | 0.76 | FPR2 (0.49) | FPR2 | |
| SCHEMBL2327774 | 0.74 | KLKB1 (0.35) | — | |
| SCHEMBL9900224 | 0.73 | FPR2 (0.45) | FPR2 | |
| SCHEMBL1704241 | 0.73 | FPR2 (0.46) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| JP-4656674-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | claimed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | claimed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | claimed |
| EP-2648724-B1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| EP-2649068-B1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8846733-B2 | Oxazolyl-methylether derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2648724-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| EP-2649068-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| WO-2012077049-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012077051-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
| EP-2225231-B1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2225231-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009077990-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331378-A1 | AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS | ADORA1, ADORA3, TBXA2R | FPR2 285/4885HRH3 294/4885HDAC6 3055/4885 |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | ADORA1, ADORA3, HCAR3 | FPR2 333/4885HRH3 44/4885HDAC6 3448/4885 |
| US-20130261159-A1 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX7, ADORA3, P2RX1 | FPR2 275/4885HRH3 188/4885HDAC6 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.